(Reuters) – Industrial materials maker DuPont (DD.N) is considering a sale of its nutrition and biosciences unit, Bloomberg reported on Tuesday, citing people familiar with the matter.
The unit, which supplies everything from soy-based food ingredients to tablet binders, could be worth at least $20 billion as a standalone entity, Bloomberg said.
DuPont declined to comment on the unit’s divestiture.
The Wilmington, Delaware-based company said in February that its overall goal was to divest about 10% of its portfolio.
DuPont was a part of DowDupont until a split earlier this year.
The nutrition and biosciences unit, DuPont’s biggest revenue generator in 2018 on a pro-forma basis, was hit by lower sales of food, beverage and pharma solutions in the latest reported quarter, and brought in 4% lower sales than a year earlier.
Reporting by Debroop Roy and Manojna Maddipatla in Bengaluru; Editing by Shinjini Ganguli